dismiss

This Thursday, Jan 25th is our next Clean Sweep Live Auction: Click to view the full catalogue and pre-bid now

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

The New York Times moly-99 report: 6 takeaways Insights from several experts on the delicate moly-99 supply chain

Researchers develop PET tracer that can measure damage caused by MS Offers advantages not found with conventional MR

Health Canada approves GE's DaTscan SPECT agent Can help distinguish Parkinson's disease from essential tremor

Peter Webner Cyclopharma appoints new Chief Executive Officer

Total-body PET/CT is nearing clinical readiness UC Davis team explores potential clinical and research applications

Large Swiss clinic installs Philips Vereos digital PET/CT system Fifth purchased worldwide

Low-dose radiation may help prevent cancer: Journal of American Physicians and Surgeons Scientist emeritus makes his case

Physicians halt life-threatening arrhythmias with stereotactic radiation First entirely noninvasive process proposed for treating ventricular tachycardia

PET tracer may help assess promising Alzheimer's treatment Visualizing progress with 18F-AV45 PET imaging agent

New nanoparticle technology may replace MR for cancer detection Shows promise in preclinical study

Nuclear medicine community asks Congress for more Mo-99 funding

by Thomas Dworetzky , Contributing Reporter
Congress has again been urged to support greater MO-99 production by SNMMI and others in the nuclear medicine community.

The letters, sent to the relevant leadership of both houses, ask for additional funds. The Senate version ups the cap on each of the existing four cooperative agreements with partners from $25 million to $35 million, an additional $10 million per agreement in FY 2018, “and would be available retroactively to each partner, as long as the partner had contributed $35 million of its own funds,” according to the letters to the House and Senate.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory



That would bring the total to $67.4 million, and would include both the increase and the $27.4 million required to meet existing obligations.

The letters, sent to the U.S. Senate and House chairs and ranking members of the respective subcommittees on energy and water development of the Committees on Appropriations, asked for the money “to secure a sufficient domestic supply of the medical isotope molybdenum-99 (Mo-99).”

“Most importantly, nuclear medicine allows physicians to better characterize the extent of disease in the body, informing more accurate treatments and better outcomes,” the letters stressed. “Through the use of Mo-99 we can detect heart disease and cancer earlier, saving millions of lives and billions of dollars each year. However, given there are no global suppliers in the Western Hemisphere, supply shortages could occur at any moment due to Mo-99’s short half-life. Therefore, the urgent need for a domestic solution as originally highlighted under AMIPA in 2012 remains unsolved.”

It was in that year that Congress passed the American Medical Isotope Production Act.

The domestic supply of Mo-99 is supported by the National Nuclear Security Administration (NNSA) at the Department of Energy (DOE), which now has four cooperative agreements with companies to produce the isotope in the U.S. using non-high-energy uranium.

In addition, research on alternatives for production (mainly using low-enriched uranium) has been costly and taken longer than expected.

For example, as reported in May, SHINE Medical Technologies hit a money-raising snag, and now wants to build a prototype of its full-scale radioisotope-producing facility in Janesville, Wisconsin.

This could stall by three to six months the goal of commercial Molybdenum-99 production at SHINE's to-be-built $100 million, 57,000 square-foot main plant in Janesville, Wisconsin, most recently scheduled for mid-2019, until 2020.
  Pages: 1 - 2 - 3 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED